PegBio (HKG:2565) reported a loss attributable to equity shareholders of the company of 93.62 million yuan for the first half of 2025, compared with a loss of 155.37 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the biotechnology firm were up over 1% in Wednesday late-morning trade.
Loss per share came in at 0.25 yuan, compared with 0.42 yuan in the prior-year period.
Other net income was 178,000 yuan, compared with 4.05 million yuan a year earlier.
The firm said it has no products approved for commercial sale and has not generated any revenue from product sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.